
Noom Expands Blood Testing, Gene Editing Targets Cholesterol, Retro Biosciences Surges
29/05/2026
0:00
2:42
May 29, 2026: Your daily rundown of health and wellness news, in under 5 minutes.
Today's top stories:
- Noom launches at-home biomarker kits measuring 17 markers with microneedle collection, finding 70% of users have high LDL cholesterol despite appearing healthy
- Scientists report single gene-editing infusion lowering LDL cholesterol by 62% with results maintained 18+ months, potentially replacing years of daily medication
- Retro Biosciences reaches $1.8B valuation backed by Sam Altman, entering human trials testing cellular cleanup process to combat neurodegeneration and age-related disease
More from Fitt:
Fitt Insider breaks down the convergence of fitness, wellness, and healthcare — and what it means for business, culture, and capital.
Subscribe to our newsletter → insider.fitt.co/subscribe
Work with our recruiting firm → https://talent.fitt.co/
Follow us on Instagram → https://www.instagram.com/fittinsider/
Follow us on LinkedIn → linkedin.com/company/fittinsider
Reach out → [email protected]
D'autres épisodes de "Fitt Insider"



Ne ratez aucun épisode de “Fitt Insider” et abonnez-vous gratuitement à ce podcast dans l'application GetPodcast.








